A
Menu
First published November 02, 2023 Application Aachen patent A – Human necessities

PSEUDO-DISACCHARIDE COMPOUNDS

Espacenet Family 83439016

Abstract

Provided herein are compounds of formula (I), or a pharmaceutically acceptable salt, solvate, or prodrug thereof: The substituents are as defined herein. Also provided are pharmaceutical compositions comprising the compounds, as well as use of the compounds as a medicament. The compounds or compositions are also useful for inhibiting heparanase (HPSE), for example in the treatment of a condition which is modulated by heparanase. Some compounds may be used for the enzymatic labelling of heparanase.

Inventors 7

  1. Herman S. Overkleeft Aachen author as filed: Overkleeft, Herman
  2. Vincent A. J. Lit Aachen author as filed: Lit, Vincent
  3. Casper de Boer Aachen author as filed: de Boer, Casper
  4. Sybrin P. Schröder Aachen author as filed: Schröder, Sybrin
  5. Davies, Gideon
  6. Wu, Liang
  7. Valentina Borlandelli Aachen author as filed: Borlandelli, Valentina

Inventors are linked to an Aachen author when surname and first name match exactly one author.

Applicants

  • UNIVERSITEIT LEIDEN GBS Leiden
  • UNIVERSITY OF YORK
  • Univ York

Cited papers 4 in the database

Non-patent literature as cited (32)
  • - WINKLER ET AL., NAT COMMUN, vol. 11, 2020, pages 5120
  • - SARRAZIN ET AL., COLD SPRING HARB PERSPECT BIOL, 2011, pages 3
  • - WU ET AL., NAT STRUCT MOL BIOL, vol. 22, 2015, pages 1016 - 1022
  • - JAYATILLEKE ET AL., J TRANSL MED, vol. 18, 2020, pages 453
  • - NAKAJIMA ET AL., SCIENCE, vol. 220, 1983, pages 611 - 3
  • - VLODAVSKY ET AL., CANCER RES, vol. 43, 1983, pages 2704 - 11
  • - VLODAVSKY ET AL., J CLIN INVEST, vol. 108, 2001, pages 341 - 7
  • - ELKIN ET AL., FASEB J, vol. 15, 2001, pages 1661 - 3
  • - RITCHIE ET AL., CLIN CANCER RES, vol. 17, 2011, pages 1382 - 93
  • - ZHOU ET AL., PLOS ONE, vol. 6, 2011, pages e21106
  • - PARISH ET AL., CANCER RES, vol. 59, 1999, pages 3433 - 3441
  • - FERRO ET AL., J MED CHEM, vol. 55, 2012, pages 3804 - 13
  • - SUTANTO ET AL., RSC MED CHEM, vol. 11, 2020, pages 876 - 884
  • - GINGIS-VELITSKI ET AL., J BIOL CHEM, vol. 279, 2004, pages 44084 - 92
  • - BERGE ET AL.: "Pharmaceutical Salts", JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, 1977, pages 1 - 19, XP002675560, DOI: 10.1002/jps.2600660104
  • - T. HIGUCHIV. STELLA: "the A.C.S. Symposium Series", vol. 14, 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS, article "Pro-drugs as Novel Delivery Systems"
  • - "Design of Prodrugs", 1985, ELSEVIER
  • - JUDKINS ET AL., SYNTHETIC COMMUNICATIONS, vol. 26, no. 23, 1996, pages 4351 - 4367
  • - "ThermoFisher Scientific", 2010, article "The Molecular Probes Handbook: A Guide to Fluorescent Probes and Labeling Technologies"
  • - WU ET AL., NAT CHEM BIOL, vol. 13, 2017, pages 867 - 873
  • - "Remington's Pharmaceutical Sciences", 1990, MACK PUBLISHING CO
  • - POULAIN ET AL., DEVELOPMENT, vol. 142, 2015, pages 3456 - 67
  • - HAMMOND ET AL., ANAL BIOCHEM, vol. 396, 2010, pages 112 - 6
  • - VLODAVSKY ET AL., CURR. PROTOC. CELL. BIOL
  • - HALL ET AL., METHODS MOL BIOL, vol. 1070, 2014, pages 1 - 11
  • - U. BARASH ET AL., JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 110, 2018, pages 1102 - 1114
  • - M. WEISSMANN ET AL., PROC NATL ACAD SCI, vol. 113, 2016, pages 704 - 709
  • - VLODAVSKY ET AL., CURR PROTOC CELL BIOL, 2001, pages 4
  • - CHEN YURONG ET AL: "Activity-Based Protein Profiling of Retaining [alpha]-Amylases in Complex Biological Samples", vol. 143, no. 5, 10 February 2021 (2021-02-10), pages 2423 - 2432, XP093013815, ISSN: 0002-7863, Retrieved from the Internet <URL:http://pubs.acs.org/doi/pdf/10.1021/jacs.0c13059> DOI: 10.1021/jacs.0c13059
  • - SCHRÖDER SYBRIN P. ET AL: "Dynamic and Functional Profiling of Xylan-Degrading Enzymes in Aspergillus Secretomes Using Activity-Based Probes", vol. 5, no. 6, 26 June 2019 (2019-06-26), pages 1067 - 1078, XP093013820, ISSN: 2374-7943, Retrieved from the Internet <URL:http://pubs.acs.org/doi/pdf/10.1021/acscentsci.9b00221> DOI: 10.1021/acscentsci.9b00221
  • - J. P. RITCHIE ET AL: "SST0001, a Chemically Modified Heparin, Inhibits Myeloma Growth and Angiogenesis via Disruption of the Heparanase/Syndecan-1 Axis", CLINICAL CANCER RESEARCH, vol. 17, no. 6, 21 January 2011 (2011-01-21), US, pages 1382 - 1393, XP055267176, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-10-2476
  • - VITO FERRO ET AL: "Discovery of PG545: A Highly Potent and Simultaneous Inhibitor of Angiogenesis, Tumor Growth, and Metastasis", JOURNAL OF MEDICINAL CHEMISTRY, vol. 55, no. 8, 13 April 2012 (2012-04-13), US, pages 3804 - 3813, XP055493094, ISSN: 0022-2623, DOI: 10.1021/jm201708h

Cited patents 1

US2010036001A1